Bispecific Antibody Market

Bispecific Antibody Market Outlook (2023 to 2033)

The global biospecific antibody market is slated to reach a market value of US$ 500 million by the end of 2023, and eventually to US$ 1 billion by 2033, marking a CAGR of 7.2%.

Data Points	Key Statistics
Expected Market Value in 2023	US$ 500 million
Projected Market Value in 2033	US$ 1 billion
Growth Rate (2023 to 2033)	7.2% CAGR

Revolutionizing Targeted Therapy: The drivers behind Bispecific Antibody Market Growth

Antibody engineering has been a crucial driver of the bispecific antibody market. In recent years, significant progress has been made in developing novel antibody formats and engineering techniques that enable the generation of bispecific antibodies with enhanced efficacy and stability. For example, advances in recombinant DNA technology and protein engineering have enabled the construction of bispecific antibodies that have improved pharmacokinetics, reduced immunogenicity, and increased tumor penetration.

The bispecific antibody market is also being driven by the increasing prevalence of cancer and autoimmune diseases. These diseases remain a significant unmet medical need, and the development of novel and effective therapies is crucial for improving patient outcomes. Bispecific antibodies have shown promise in the treatment of cancer and autoimmune diseases, as they can target two different antigens simultaneously and thereby enhance therapeutic efficacy. For example, blinatumomab, a bispecific antibody targeting CD19 and CD3, has been approved for the treatment of B-cell acute lymphoblastic leukemia (ALL) and is currently being evaluated for other hematologic malignancies.

Unleashing the Potential of Bispecific Antibodies: Exploring the Latest Opportunities in Targeted and Personalized Therapy

The latest opportunities in the bispecific antibody market are mainly driven by the growing demand for targeted and personalized therapies and the emergence of novel bispecific antibody formats and technologies.

The growing interest in novel bispecific antibody formats and technologies is a prominent opportunity for bispecific antibody market. Over the past few years, several innovative BsAb platforms have emerged, enabling the creation of bispecific antibodies with enhanced pharmacokinetic and pharmacodynamic properties. For instance, bispecific T-cell engagers (BiTEs) are a class of BsAbs that can redirect T-cells to recognize and attack cancer cells, and they have shown impressive results in clinical trials. Similarly, bispecific antibody fragments, such as nanobodies and Fynomers, have shown promise in overcoming the limitations of traditional full-length bispecific antibodies, such as poor stability and low expression yields.

The bispecific antibody market is expected to benefit from the increasing demand for personalized and targeted therapies. BsAbs can be designed to selectively target specific cell types or molecules, allowing for a more precise and effective therapy with fewer side effects. This personalized approach is particularly relevant in the context of rare diseases, where traditional therapies may not be available or effective.

Development of Bispecific Antibody Market in North America

The North American region is an eminent contributor to the global bispecific antibody market. The United States (US) is the largest market for bispecific antibodies in North America, with a substantial share of the global market. Canada is also an important market for bispecific antibodies in North America, with a growing focus on the development of innovative bispecific antibody platforms and technologies. The country has a strong research and development infrastructure, with a significant number of biotechnology companies and academic institutions working on the development of bispecific antibody drugs.

The North American region has seen a growing interest in novel bispecific antibody formats and technologies, such as nanobodies and Fynomers. These innovative platforms allow for the creation of bispecific antibodies with enhanced pharmacokinetic and pharmacodynamic properties, leading to more effective and personalized therapies.

The increasing focus on personalized and targeted therapies is a prominent factor driving the growth of the bispecific antibody market in North America. This personalized approach is particularly relevant in the context of rare diseases, where traditional therapies may not be available or effective.

The bispecific antibody is used for therapeutic effects by targeting two or more pathways which often lead to the root of the disease. In this, two or more antigen identifying elements are blended into one.

Bispecific antibody generates better results and minimal side effects at low cost treatment. This potential therapeutic effect of bispecific antibody against more than one disease at a time is estimated to grow bispecific antibody market.

Bispecific antibody covers a wide spectrum of diseases like oncological, inflammatory and autoimmune disorders, rejection of organ transplants, cardiovascular diseases, allergies, ophthalmic problems and infectious diseases.

According to WHO, the cancer and cardiovascular disorders are the leading causes of death and this unmet need of novel therapies is expected to meet by bispecific antibody therapies.

COVID-19 pandemic is expected to delay in the clinical research and subsequent launch of new therapies in the bispecific antibody market. Declining rate of hospitalization and treatment adoption are expected to impact negatively on bispecific antibody market.

In addition, the supply chain of bispecific antibody market is projected to impact owing to restriction on trading between several countries. Since 2015 when bispecific antibody market was established there has been exponential growth in terms of revenue generation.

With an increase in research and development activities for the bispecific antibody, the leading industry players are investing in the bispecific antibody. A large number of products under clinical trials will lead to the treatment of numerous disorders with a single approach making bispecific antibody market in most demand.

High acceptance rate among clinicians and patients due to target specific treatment has boomed bispecific antibody market. With an increase in the prevalence of chronic disorders across the globe acts as a driving force for bispecific antibody market.

However, bispecific antibodies are not an exception and have side effects which limit the growth of bispecific antibody market. Blinatumomab drug type is the highest revenue-generating in the bispecific antibody market.

The bispecific antibody market is estimated to grow exponentially in the coming decade. By indication, cancer is projected as a highest revenue generating segment owing to large patient pool.

Amongst the distribution channel, the hospital pharmacies is estimated to generate highest revenue followed by retail pharmacies. Whereas, online pharmacies are expected to have significant growth rate during the forecast period with advancements in digital technology in the bispecific antibody market.

North America dominates the bispecific antibody market owing to high prevalence of chronic diseases and cancer in this region. Europe is the second-lucrative region for bispecific antibody market owing to development and launch of novel bispecific antibody products in this region.

Asia-Pacific bispecific antibody market is expected to increase substantially owing to high patient pool in the region. Latin America and Middle East & Africa bispecific antibody markets are least lucrative due to unfavourable economic conditions and less healthcare expenditure.

Some key players contributing in bispecific antibody market are

• Sonafi S.A.
• AbbVie Inc.
• Pfizer Inc.
• Johnson & Johnson
• Portola Pharmaceuticals
• Bristol-Myers Squibb
• Ganymed Pharmaceuticals
• OncoMed Pharmaceuticals
• Merck Amgen
• Bayer AG
• Daiichi Sankyo Company Limited

The research report on bispecific antibody market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on bispecific antibody market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes

• North America (USA, Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, Italy, France, United Kingdom, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Bispecific antibody market Segmentation

The global bispecific antibody market is classified based on drug type, indication, distribution channel and region.

By Drug Type:

• Blinatumomab
• Catumaxomab
• Duligotumab

By Indication:

• Cancer
• Infectious Disease
• Inflammatory and Autoimmune Disorders
• CNS Disorders

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drugstores
• Online Pharmacies